Gastrointestinal Cancer News

Researchers observed a significant reduction in overall risk of cancer among individuals who consumed organic food at a high frequency, according to a new study published in JAMA Internal Medicine.

MUNICH — Women appeared more likely than men to experience certain side effects from first-line chemotherapy for esophagogastric cancer, according to study results presented at European Society for Medical Oncology Congress.

A team of physicians from the Baylor College of Medicine and the Texas Children’s Cancer Center’s Pediatric Liver Tumor Program have begun using a state-of-the-art treatment known as transarterial radioembolization to treat children with liver tumors, according to a press release.

MUNICH — Nearly one-quarter of patients with metastatic cancer who underwent comprehensive genomic profiling at National Comprehensive Cancer Network centers in the United States received a genomically matched treatment, according to study results presented at European Society for Medical Oncology Congress.

The FDA granted orphan drug designation to olaparib for the treatment of patients with pancreatic cancer, according to the agent’s manufacturer.

Most carriers of genetic mutations known to increase the risk for breast, ovarian, prostate and pancreatic cancers appeared unaware of their mutation carrier status despite frequent interactions with the health care system, according to results of a cross-sectional study published in JAMA Network Open.

Naresh T. Gunaratnam, MD, a gastroenterologist and research director at Huron Gastroenterology in Ypsilanti, Michigan , provided data for Cologuard’s initial validation study. In this guest commentary, Gunaratnam discusses that while the colorectal cancer screening tool is an appropriate choice when a patient refuses a colonoscopy, the way in which Cologuard is being marketed presents concerns for gastroenterologists.

A combination of interventions, particularly those that include fecal blood test outreach and patient navigation, were linked to improvements in completion of colorectal cancer screening, according to findings published in JAMA Internal Medicine.

More teenagers aged between 13 and 17 years received the HPV vaccine in 2017 than 2016, with 65.5% administered at least one dose and 48.6% completing the three-dose series, according to the CDC. However, many barriers to HPV vaccination exist in rural areas, where HPV-related cancers are more prevalent.

PHILADELPHIA — In this exclusive video from the American College of Gastroenterology Annual Meeting, Nicholas J. Shaheen, MD, MPH, FACG, from the University of North Carolina, talks about a study he presented on the WATS3D system.